The US Association for Accessible Medicines has urged Congress to consider the economic impact of the proposed Blocking Act and re-evaluate the need for the legislation, which the AAM says threatens to “roll back the progress made by the Trump administration and the bipartisan efforts in Congress to lower prescription drug costs for patients.”
The Blocking Act contains reforms to the country’s 180-day exclusivity incentive for first generics that successfully challenge originator patents. Under...
